Eldar S, Kemeny M M, Benfield J R
Surg Gynecol Obstet. 1982 Dec;155(6):829-32.
In conclusion, patients with hairy-cell leukemia may need no therapy for prolonged periods. If they are symptomatic from hypersplenism, they may be expected to benefit from splenectomy. Some patients will have a relapse after splenectomy. At this time, there is no method to predict which patients will have a long term benefit from splenectomy, and we believe that operation should not be recommended as the primary therapy for hairy-cell leukemia.